Crit Care. 2008;12(6):193. Epub 2008 Nov 24.

Does tirofiban prevent platelet loss in patients after cardiogenic shock during continuous renal replacement therapy?

Source

Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany. christian.storm@charite.de

Abstract

Link and colleagues present a pilot study investigating platelet function and platelet numbers in patients with cardiogenic shock and acute kidney failure undergoing continuous venovenous haemodialysis. Their data indicate a significantly reduced platelet loss with combined therapy of unfractionated heparin plus tirofiban, the glycoprotein IIb/IIIa antagonist, compared with unfractionated heparin therapy alone. Owing to the small sample size, however, the potential impact of additional treatment variables (antiplatelet agents, intraaortic counterpulsation) could not be clarified. A substantially larger, adequately powered study is therefore called for to establish the potential clinical relevance of these findings.

Comment on

Crit Care. 2008;12(4):R111.

PMID:: 19040776; [PubMed - indexed for MEDLINE]
PMCID: PMC2646330

Free PMC Article

Publication Types, MeSH Terms, Substances

Publication Types

Comment

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Shock - MedlinePlus Health Information

Molecular Biology Databases

Libraries

LinkOut Holdings

Supplemental Content

Related citations

Tirofiban preserves platelet loss during continuous renal replacement therapy in a randomised prospective open-blinded pilot study. [Crit Care. 2008]
Tirofiban preserves platelet loss during continuous renal replacement therapy in a randomised prospective open-blinded pilot study.
Link A, Girndt M, Selejan S, Rbah R, Böhm M. Crit Care. 2008; 12(4):R111. Epub 2008 Aug 29.
Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban. [Anesthesiology. 2001]
Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban.
Koster A, Kukucka M, Bach F, Meyer O, Fischer T, Mertzlufft F, Loebe M, Hetzer R, Kuppe H. Anesthesiology. 2001 Feb; 94(2):245-51.
Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. [J Am Coll Cardiol. 1996]
Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty.
Kereiakes DJ, Kleiman NS, Ambrose J, Cohen M, Rodriguez S, Palabrica T, Herrmann HC, Sutton JM, Weaver WD, McKee DB, et al. J Am Coll Cardiol. 1996 Mar 1; 27(3):536-42.
Review Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT. [Drugs. 1998]
Review Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
Alexander JH, Harrington RA. Drugs. 1998 Dec; 56(6):965-76.
Review Tirofiban. A review of its use in acute coronary syndromes. [Drugs. 1998]
Review Tirofiban. A review of its use in acute coronary syndromes.
McClellan KJ, Goa KL. Drugs. 1998 Dec; 56(6):1067-80.

See reviews... See all...

Cited by 1 PubMed Central article

Review Year in review 2008: Critical Care--nephrology. [Crit Care. 2009]
Review Year in review 2008: Critical Care--nephrology.
Ricci Z, Ronco C. Crit Care. 2009; 13(5):227. Epub 2009 Oct 21.

Chemical compound information

tirofiban

MW: 440.59 g/mol

MF: C₂₂H₃₆N₂O₅S

See 1 citation for this compound....

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
References for this PMC Article
Citation referenced in PubMed article. Only valid for PubMed citations that are also in PMC.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Free in PMC
Free full text articles in PMC
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Does tirofiban prevent platelet loss in patients after cardiogenic shock during ...
Does tirofiban prevent platelet loss in patients after cardiogenic shock during continuous renal replacement therapy?
Crit Care. 2008 ;12(6):193. Epub 2008 Nov 24 .

PubMed
Effects of alfa-hydroxy-isocaproic acid on body composition, DOMS and performanc...
Effects of alfa-hydroxy-isocaproic acid on body composition, DOMS and performance in athletes.
J Int Soc Sports Nutr. 2010 Jan 5 ;7:1.

PubMed
Prospective evaluation of an internet-linked handheld computer critical care kno...
Prospective evaluation of an internet-linked handheld computer critical care knowledge access system.
Crit Care. 2004 Dec ;8(6):R414-21. Epub 2004 Oct 14 .

PubMed
Accuracy of spinal orthopaedic tests: a systematic review.
Accuracy of spinal orthopaedic tests: a systematic review.
Chiropr Osteopat. 2006 Oct 31 ;14:26.

PubMed
Online assessment of patients' views on hospital performances using Rasch model'...
Online assessment of patients' views on hospital performances using Rasch model's KIDMAP diagram.
BMC Health Serv Res. 2009 Jul 31 ;9:135.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: